Home Neoplasma 2019 Neoplasma Vol.66, No.2, p.232-239, 2019

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.66, No.2, p.232-239, 2019

Title: Circ-ITCH regulates triple-negative breast cancer progression through the Wnt/β-catenin pathway
Author: S. T. Wang, L. B. Liu, X. M. Li, Y. F. Wang, P. J. Xie, Q. Li, R. Wang, Q. Wei, Y. H. Kang, R. Meng, X. H. Feng

Abstract: Recent studies indicate that circular RNA (circRNA) is involved in tumorigenesis, but its role in triple-negative breast cancer (TNBC) remains largely unknown. In this study, we characterized the role of circ-ITCH in TNBC and found that circ-ITCH was significantly down-regulated in TNBC tissues and cell lines and closely associated with poor prognosis. We therefore constructed the MDA-MB-231 and BT-549 TNBC cell lines stably expressing circ-ITCH by lentiviral vectors to determine its underlying mechanisms in TNBC progression. Most importantly, over-expression of circ-ITCH remarkably inhibited TNBC proliferation, invasion and metastasis both in vitro and in vivo. Mechanistically, we found that circ-ITCH acts as a sponge for miR-214 and miR-17 to increase expression of its ITCH linear isoform, thereby inactivating Wnt/β-catenin signaling. Our combined results show for the first time that circ-ITCH is a tumor suppressor, a promising prognostic biomarker in TNBC and that its restoration could well be a successful strategy in TNBC.

Keywords: CircRNA, Circ-ITCH, TNBC, prognosis, metastasis
Published online: 19-Mar-2019
Year: 2019, Volume: 66, Issue: 2 Page From: 232, Page To: 239
doi:10.4149/neo_2018_180710N460


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.